$XBI $69.40 | +2.25%
Table of Contents:
Covid Updates
$AKTX +7.6% Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting source
Pipeline Updates
$MRTX -6.8% Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer source
$FHTX -25.8% Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS source
$ACRX +27.6% AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® source
$TCDA +4.0% Tricida Announces Administrative Stop of the VALOR-CKD Trial source
$CALT +18.0% Calliditas receives positive CHMP opinion in IgA nephropathy source
$CLBS +1.0% Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease source
$SIGA +17.1% SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) source
$MRSN +4.9% Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer source
$ALRN +0.7% Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer source
$RCKT +0.5% Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$
Posted by JM